Skip to main content

InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) Eyes New Opportunities, Looks to ‘Watershed’ Year as Focus Groups Report Impressive Results

Pressure BioSciences (OTCQB: PBIO), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumable products, and specialty services to the life sciences, nutraceuticals, cosmeceuticals and other industries, is reporting on a consumer focus group. The focus group was designed to test a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks and prepared with PBI’s revolutionary Ultra Shear Technology(TM) platform by PBI’s California-based partner companies, including Crème De Canna, a California-licensed manufacturer and long-established provider of innovative, high-quality cannabis products. The focus group showed speedy onset of first effects, much faster progression to maximum effects, the elimination of health issues associated with smoking or vaping and enormous efficiency improvement in dose payload delivery. In addition, the company noted that subsequent consumer focus group testing strongly affirmed these pivotal results. “These extended study results have confirmed the potential for a market transformation in THC consumption with a new oral/transdermal dosing modality in between the existing smoke/vape and edible food/beverage bifurcation of this enormous market,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “We believe that the customer experience with UltraShear processed Nano-THC will be compelling to drive a tidal change in the market, with potential explosive adoption of UltraShear processed Nano-THC. . . . 2023 is poised to be a watershed transformational year for PBI, as we capitalize for roll-out of the UltraShear platform and converge upon our announced NASDAQ or NYSE uplisting goal.”

In addition, Pressure BioSciences is also positioning itself to leverage new opportunities across the life sciences space. A growing biosimilar market has created an ideal opportunity for PBI’s pressure-based BaroFold system, which the company designed to provide researchers with precision control as they manipulate the unfolding and refolding of the protein drug candidates and other cell materials that are essential to so many of the top biologics in development. The company noted that BaroFold’s added precision can improve the efficiency of the manufacturing process and the quality of the resultant drug candidate as well as potentially level up the safety and efficacy of the drugs made. The company is also in an ideal position to make the most of a growing interest in cannabis. “PBI’s UltraShear(TM) Technology platform is tailor-made to produce high-quality CBD nanoemulsions,” the announcement states. “It does this by breaking down the CBD oil into droplets that are so small, they effectively become water-soluble. That can turn an active ingredient contained in the oil that is typically poorly absorbed by the human body into one that’s more easily and more consistently absorbed.

For the pharma companies working on cannabis-derived therapeutics, that improved absorption is key to delivering more precise dosing and developing drugs with more consistent and reliable therapeutic effects. That could be a game changer for medical cannabis research, which has been plagued by promising but inconsistent clinical results due to the low and unpredictable absorption rates of most cannabis-derived compounds.

To view the full press releases, visit and

About Pressure BioSciences Inc.

Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical and agrochemical, as well as food and beverage manufacturing. The company’s products utilize both constant and alternating pressure. Its patented enabling technology platform — Pressure Cycling Technology (“PCT”) — utilizes alternating cycles of pressure to control biomolecular interactions, such as cell lysis and biomolecule extraction, safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counterbioterrorism applications. PBIO has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing the company to enter the biopharma contract services and GMP manufacturing equipment sector. The company has also developed the scalable and high-efficiency pressure-based UltraShear Technology platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information, visit the company website at

NOTE TO INVESTORS: The latest news and updates relating to SYATF are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.